• Meet CTI
    • Corporate Strategy
    • Milestones
    • Technologies
    • Our People & Subsidiaries
    • Collaborations & Partnerships
    • FAQ
    • Community Involvement
  • Development
    • Zevalin®
    • Pixantrone
    • OPAXIO™
    • Brostallicin
    • Novel Bisplatinum Analogues
    • Medical Inquiries for Healthcare Professionals
    • Medical Inquiries for Patients & Caregivers
  • Products
    • Zevalin®
  • Clinical Trials
    • Patient Resources
    • Lung Cancer Clinical Trials
    • Ovarian Cancer Clinical Trials
    • Other Clinical Trials
  • Investors
  • Press Room
    • News
    • Press Kits
    • Media Library
    • Media Contacts
  • Careers
    • Compensation & Benefits
    • Living in Seattle
    • Job Opportunities
ItalianoSiteMap 
News
Stock
SEC Filings
Webcasts
Corporate Calendar
Investor Updates
Annual Reports
Financial Details
Balance Sheet
Cash Flow
Income Statement
Ratios
Corporate Governance
Investor FAQ
Information Request
Email Alerts
Print this page Print this page
Email this page Email this page

Snapshot

Show Fundamentals in an Interactive Chart
Revenue & Earnings
Revenue (mil) (FYE).13
Income From Continuing Operations (mil) (FYE)-138.11
Income From Total Operations (mil) (FYE)-138.11
Diluted EPS From Continuing Operations (FYE)-32.74
Diluted EPS From Total Operations (FYE)-32.70
Dividends
Ex-Dividend Date
Dividend Rate.00
Yield.00%
Yield - 5 Year Average.00
Ratios
Price To Revenue4.71
Price To Cash Flow-.01
Price to Book.00
Debt To Equity-103.84
Current Ratio.42
Growth Rates
5-Year Annual Dividend Growth Rate.00
5-Year Annual Revenue Growth Rate-62.40
Data Provided by Thomson Financial


CTI Fact Sheet (201K PDF)
Most Viewed Links
1.Current News Release
2.Stock Quote
3.Comunicati stampa
4.SEC Filings
5.Press Room
© 2008 Cell Therapeutics, Inc. All rights reserved.
Privacy PolicyTerms and ConditionsContact CTI